RECRUITING

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Talk to us

Conditions

Prostate CancerPSMA-PET

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy

Official Title

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Quick Facts

Study Start:2025-08-15
Study Completion:2028-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07011342

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult males 18 years or older;
  2. * Patient must have a pre-treatment MRI;
  3. * Patient underwent SOC focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months prior to enrollment;
  4. * Intermediate risk disease as defined by American Urology Academy (AUA)/National Comprehensive Cancer Network (NCCN) guidelines (see Appendix A)
  5. * Life Expectancy of 10 years or more;
  6. * Underwent standard template biopsy before treatment with a minimum of 2 cores into the MRI visible lesion if lesion was present;
  7. * Patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol; and
  8. * Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points.
  1. * Patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a unique population outside the scope of this study as it is aimed at identifying factors that affect adults only.
  2. * Patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.

Contacts and Locations

Study Contact

Oncology Clinical Research Referral Office
CONTACT
551-996-1777
OncologyResearchReferral@hmhn.org

Principal Investigator

Nitin Yerrman, MD
PRINCIPAL_INVESTIGATOR
Hackensack Meridian Health

Study Locations (Sites)

John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601
United States

Collaborators and Investigators

Sponsor: Hackensack Meridian Health

  • Nitin Yerrman, MD, PRINCIPAL_INVESTIGATOR, Hackensack Meridian Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-15
Study Completion Date2028-10

Study Record Updates

Study Start Date2025-08-15
Study Completion Date2028-10

Terms related to this study

Keywords Provided by Researchers

  • PSMA-PET

Additional Relevant MeSH Terms

  • Prostate Cancer